CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

Boehringer Ingelheim, a biopharmaceutical firm that manufactures medicine for humans and animals, has relocated to a ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ($31.06 million) to a new R&D facility specifically focused on the modality.

Boehringer Ingelheim struggled to convince a three-judge panel Thursday that the US government’s drug price negotiation plan ...

Coffee in hand, Johns Creek? We've got the latest town updates for you. Keep reading to stay in the loop. ☕️️ In today's ...

Hi there, Johns Creek! We've got your morning read ready! Read on to stay connected. ☀️ In today's newsletter: Boehringer Ingelheim moves HQ to Johns Creek Perry Greene apologizes for hate incident ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Xi previously called together Chinese CEOs for a highly publicized meeting in which he offered greater protection for the ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...